Octreotide

Octreotide (SMS 201-995) is a synthetic cyclic octapeptide analog of somatostatin-14 that reproduces the pharmacologically essential tetrapeptide core (Phe-Trp-Lys-Thr) of the native hormone within a conformationally constrained disulfide-bridged ring, yielding a compound with high-affinity binding at somatostatin receptor subtype 2 (SSTR2; Ki approximately 0.4 to 0.6 nanomolar), moderate affinity at SSTR5 (Ki approximately 7 nanomolar) and SSTR3 (Ki approximately 35 nanomolar), and negligible affinity at SSTR1 and SSTR4 [1, 2]. The compound was synthesized at the Sandoz Forschungsinstitut in Basel by Bauer, Briner, Doepfner, and colleagues in 1982, selected from a series of conformationally stabilized somatostatin fragments on the basis of a 45-fold increase in potency for growth hormone inhibition relative to somatostatin-14 in an in vitro rat pituitary bioassay and a 30-fold selectivity for growth hormone suppression over insulin suppression, a therapeutic index absent from the native tetradecapeptide [1]. The critical structural innovation was the introduction of a D-Trp at position 4 and D-phenylalanol at the C-terminus within a cystine-bridged octapeptide ring that resisted enzymatic degradation and extended the plasma elimination half-life from the approximately 1 to 3 minutes of native somatostatin to approximately 90 to 120 minutes after subcutaneous injection in humans [3, 4]. Octreotide received United States Food and Drug Administration approval in 1988 for the symptomatic management of acromegaly and for the control of symptoms associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). The long-acting release (LAR) intramuscular depot microsphere formulation (Sandostatin LAR, Novartis) was approved in 1998, enabling once-monthly administration at 10, 20, or 30 milligram doses. An oral octreotide capsule formulation (Mycapssa, Chiasma/Amryt) employing a transient permeability enhancer technology received FDA approval in 2020 for long-term maintenance therapy in acromegaly patients previously responding to injectable somatostatin receptor ligands [5]. The antiproliferative activity of octreotide LAR in metastatic midgut neuroendocrine tumors was established in the PROMID trial (Rinke et al. 2009), a placebo-controlled randomized study demonstrating a median time to tumor progression of 14.3 months versus 6.0 months on placebo (hazard ratio 0.34, p equal to 0.000072) [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (peak plasma concentration at 25 to 30 minutes), high bioavailability (approximately 100 percent), plasma protein binding of approximately 65 percent predominantly to lipoprotein, hepatobiliary metabolism, and renal elimination of approximately 32 percent of the dose as unchanged drug [3, 4]. The principal adverse effects are gastrointestinal (diarrhea, nausea, abdominal discomfort in 30 to 50 percent of patients, typically self-limiting), cholelithiasis (gallstone or biliary sludge formation in 15 to 30 percent on chronic therapy, attributable to inhibition of cholecystokinin-mediated gallbladder contraction and bile flow), and alterations in glucose homeostasis (suppression of insulin and glucagon secretion producing hyper- or hypoglycemia depending on the metabolic context) [7, 8]. This monograph documents the chemistry, synthesis, and structural pharmacology of octreotide; the somatostatin receptor subtype binding profile and downstream signaling; the comprehensive human pharmacokinetic record across subcutaneous, intramuscular depot, and oral formulations; the clinical evidence base across acromegaly, neuroendocrine tumors, carcinoid syndrome, VIPomas, variceal bleeding, and investigational indications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety record; and a structured comparative assessment of five somatostatin-pathway agents (lanreotide, pasireotide, pegvisomant, paltusotine, lutetium-177 DOTATATE) against octreotide on five competency standards.